pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
165
stories
11h
STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals
stat
11h
Novo setback casts doubt on a new way to treat heart disease
biopharma dive
12h
Novo Nordisk rocked by late-stage cardiovascular drug failure
endpoints
12h
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
13h
STAT+: Up and down the ladder: The latest comings and goings
stat
14h
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
stat
15h
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
stat
19h
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
fiercebiotech
1d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
2d
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
biospace
2d
7 companies hiring in New York now
biospace
2d
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
2d
GSK cost-cutting plan includes global layoffs
biospace
2d
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
2d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
3d
FDA offers updated guidance for generics of weight loss blockbusters
endpoints
3d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
3d
An eye drug biotech banks $118M and stocks its executive suite
biopharma dive
3d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
4d
‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug
fiercebiotech
4d
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
biospace
7d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
7d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
7d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
7d
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
stat
8d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
8d
STAT+: European regulators take steps to bolster clinical trial transparency
stat
8d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
8d
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
8d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
← prev
page 1 of 6
next →
